Physician profile
Roy D Brod
NPI 1235174483
$3,411.85
in general payments reported to CMS, 2019-2025
20 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $219 · 2021: $62.87 · 2022: $255 · 2023: $775 · 2024: $1,027 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,423.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,339.83 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $518.25 | 2019-2025 | Vabysmo |
| Abbvie INC. | $400.80 | 2022-2025 | Ozurdex, Botox |
| Apellis Pharmaceuticals, INC. | $399.44 | 2022-2025 | Syfovre |
| Alimera Sciences, INC. | $134.06 | 2019-2024 | Iluvien, Yutiq |
| Sun Pharmaceutical Industries INC. | $124.99 | 2024 | |
| Allergan, INC. | $73.53 | 2019-2021 | |
| Sandoz INC. | $67.29 | 2024 | Cimerli |
| Bausch & Lomb Americas INC. | $48.47 | 2023-2024 | Xipere, Visudyne |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $42.89 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $41.53 | 2025 | Iluvien, Yutiq |
| Harrow Eye, LLC | $34.68 | 2025 | Iheezo |
| Eyepoint US, INC. | $32.86 | 2020-2021 | |
| Astellas Pharma US INC | $32.67 | 2025 | Izervay |
| Genentech, INC. | $29.70 | 2024 | Vabysmo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyera Pharmaceuticals, LLC | $26.87 | 2019-2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.15 | 2019 | |
| Biogen, INC. | $13.20 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Brod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.